Todd Cohen

Chief Business Officer @DFI_Bio | Healthcare Investor | NY Giants fan

[DFI @DFI_Bio]

Rising costs and fierce global competition are rewriting the biotech playbook—fast.

Today’s Fierce Biotech piece underscores a vital point and a DFI mantra: being first on the rightbiology isn’t optional; it’s the only way to win. That conviction guides our work on the first- and only-in-class anti-CD20 × CD40 bispecific antibody now moving through development.

How DFI navigates the landscape:

• Double-down on first-in-class, well-validated targets. We channel capital into programs with the clearest mechanistic rationale and highest patient impact potential

• Prune ruthlessly. Anything that can’t clear a high bar for clinical differentiation or capital efficiency comes off the board—no sunk-cost thinking

• Keep the runway long. Disciplined spend stretches resources so breakthroughs, not budgets, define our timelines

By focusing on validated biology + unmet need, we can out-innovate, out-execute, and ultimately bring transformative medicines to patients despite a tougher macro climate.

https://t.co/2l5eCYXrsg

[DFI @DFI_Bio]

https://t.co/MS3ufNRvAr

[Todd Cohen @todd_cohen]

#EULAR2025 kicking off today and I’m excited to learn.
DFI has been hard at work on our novel anti-CD20xCD40 BsAb, a only-in-class bispecific designed to safely reset immune balance through a unique mechanistic synergy between highly validated pathways @DFI_Bio

[Todd Cohen @todd_cohen]

Great to see #Cell & #GeneTherapy pioneers urging the FDA to cut red tape. China is iterating fast; streamlined U.S. regulation must keep pace to protect patients and American leadership.

#FDA #RegulatoryReform #Biotech #Innovation @DFI_Bio
https://t.co/Bi80Fq4qpF

[DFI @DFI_Bio]

A deceptively simple idea with profound potential: CD20xCD40.

DFi’s bispecific antibody is designed to trigger an immune reset without CRS, without off-target suppression.

Learn more: https://t.co/3UsEoUJo7T

[DFI @DFI_Bio]

As #ASCO25 continues, we remain attuned to the high unmet need in liquid tumor treatment.

DFI is developing an anti-CD20xCD40 BsAb focused on what current therapies miss: targeting co-expressed proteins driving a significant share of B-cell malignancies.

Learn more: https://t.co/u8Peo3d7fK

[Todd Cohen @todd_cohen]

A new class of bispecific antibody beyond T cell engagers (TCE) for leukemia and lymphoma:

Anti-CD20 x CD40 BsAb #ASCO2025 @DFI_Bio